Oppenheimer analyst Hartaj Singh assumed coverage of Allogene Therapeutics with an Outperform rating and $28 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
- Allogene Therapeutics provides additional ALLO-501/501A Phase 1 data
- Allogene Therapeutics Announces Departure of Chief Financial Officer
- Allogene Therapeutics CFO Eric Shcmidt to step down
- Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano